How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any equality issues that need special consideration and are not covered in the medical technology consultation document?

Evidence generation plan

Open for comments Open until   Request commenting lead permission

We have updated this service so that members of the same organisation can now collaborate on a joint online response.

Read our blog to learn more.

5 Minimum evidence standards

All 5 AI software technologies have some clinical evidence suggesting that they increase ADR as measured by risk ratios. However the committee concluded that ADR does not capture the full clinical benefit, particularly in relation to long-term outcomes like post-colonoscopy colorectal cancer rates. Evidence relating to this was not seen for any technologies. None of the technologies reported any safety concerns.

Further to this, the committee has indicated that it may be able to recommend AI software technologies in this topic area, in the future, that have evidence for the impact of the technology on the:

  • improvement of ADR, by adenoma type and size

  • change in post-colonoscopy colorectal cancer rates

  • clinical management following polyp identification.